DeepTech for longevity and mental health
Engineered fungi that make new molecules for the mind.
We use AI and synthetic biology to design non-psychedelic neuroplastogens: compounds built to help the brain rebuild its own connections.
The brain knows how to repair itself. It only lacks the right signal. We found that signal underground.
Three networks.
One shape.
-
The sign
The “o” of æon is a ring of nodes around an active centre: a molecule and a network at once, with no beginning and no end.
-
Mycelium
Underground, ancestral, alive. Fungi have spent millions of years evolving chemistry that talks to other living systems.
-
Neurons
Neuroplasticity: the mind can reconfigure itself. Our molecules are designed to support that capacity rather than mask symptoms.
-
Cosmos
Orbits, trajectories, deep time. Aeon means an age without measure, and longevity is the question we care about most.
Living longer is not the same as living well.
- Healthy life expectancy
- 62.8 years
- Years in poor health
- 10.5 years
74%
of all deaths are now due to chronic diseases, up from 58% in 2000.
57M
people live with dementia. Deaths have tripled since 2000.
1B+
people live with a mental disorder, including 332 million with depression.
2.1B
people will be aged 60 or over by 2050, 22% of the world’s population.
Pharma has managed the mind for fifty years. It hasn’t healed it.
1 in 3 patients reach remission on antidepressants.
1 in 2 chronic patients experience withdrawal.
1 in 4 users have taken antidepressants for 10+ years.
Sources: WHO Global Health Estimates; WHO Dementia, Mental Health and Ageing fact sheets; UN World Population Prospects 2024; IHME GBD 2023; STAR*D, Rush et al., Am J Psychiatry 2006; Davies & Read, Addictive Behaviors 2019; CDC NCHS Data Brief 283.
Heal the mind at its source.
Engineered fungi produce biosynthetic neuroplastogens. Our lead program targets a single switch in the brain’s own repair system.
Neuroregeneration
Designed to help rebuild lost connections.
Neurogenesis
Supporting new neurons in the hippocampus.
Neuroprotection
Shielding neurons from cell death.
Cognitive wellness
Memory, learning, focus and mood.
The brain-repair promise studied in psychedelic research, designed without the psychedelic experience.
- Non-psychedelic
- Non-addictive by design
- Self-administered
- Fully scalable
- Cost-effective
- Built to be accessible
AI + engineered fungi = new molecules.
One R&D pipeline, from data to molecule. Each stage feeds the next.
-
01 Design
MYCENAIA engine
Our AI platform discovers and designs bioactive compounds and biosynthetic routes from omics data.
-
02 Build
Fungal biofactories
Genetic engineering and CRISPR/Cas9 to build biosynthetic pathways and high-yield producer strains.
-
03 Deliver
Tailored molecules
Compounds for mood modulation, longevity and healthspan, produced by fermentation.
Program 01 · 2026–2028
5-OH-indole derivatives
Non-psychedelic TrkB agonists, designed for a nutraceutical first path through FDA new dietary ingredient (NDI) notification, with pharmaceutical applications to follow through partnerships.
IP-first. Asset-light. B2B.
Protect
Global IP
Producer strains, bioprocesses and novel molecules, filed through USPTO, PCT and EPO.
Regulate
FDA notification
NDI notification first. Pharmaceutical development later, as a separate API through partners.
Produce
Certified CDMOs
R&D in Chile. Scale-up in the United States with cGMP-certified manufacturing partners.
Sell
B2B off-take
Ingredients for nutraceutical brands now; high-purity molecules for pharma partners later.
From engineered strain to FDA filing.
Each step de-risks the next.
-
2026 Build
- R&D team running at Merken Biotech labs
- Alliances with CROs, CDMOs and buyers
We are here
-
2027 Prove
- First Program 01 molecules
- Provisional patent at the USPTO
- Validation and pre-clinical studies
-
2028 Launch
- NDI notification submitted to the FDA
- USPTO, PCT and EPO applications
- Asset-light production and go-to-market
team → molecules → IP → FDA notification → production → B2B
Deep science, proven operators.
Core team
Leopoldo Naranjo, Ph.D.
Founder & CSO. Genetic engineering of fungi.
Felipe Muñoz, Ph.D.
Head of Strain Engineering. IBIO, UC.
Valentina Hernández
R&D Biochemist. USACH.
Board of Directors
Javier Guerrero, Ph.D.
Board member. CEO of Merken Biotech and CEO of Praxis Bio.
Advisors
Christopher Timmermann, Ph.D.
Neuroscience. Imperial College London.
Renato Chávez, Ph.D.
Fungal genetics. USACH.
David Alvo, M.Sc.
Fundraising strategy. Impacta VC.
Diego Velázquez, M.Sc.
AI and software, MYCENAIA. UNAM.
R&D alliances
Merken Biotech and Praxis Bio, two of Chile’s most experienced drug-validation companies: seven Ph.D.s with more than sixteen years of experience.
Build the next molecule with us.
We work with CDMOs, CROs, ingredient buyers, research partners and investors who share our standard: if it can’t be traced to a paper or a strain, we don’t say it.
Email lnaranjo@aeon-deep.tech